After two years in the shadows, health stocks are back as a haven for investors navigating economic uncertainty.

Janus kinase (JAK) inhibitors look to be a good treatment option for the newly recognized, rare autoimmune disease known as ...

About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.

Novartis (NVS) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has adopted a ...

The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and ...

Novartis (NYSE:NVS) announced Friday that the European Medicines Agency (EMA), endorsed Fabhalta for the treatment of adults ...

Learn more about whether Alnylam Pharmaceuticals, Inc. or argenx SE is a better investment based on AAII's A+ Investor grades ...

For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. | For GSK CEO Emma Walmsley, ...

Researchers conduct a retrospective, population-based cohort study of adult patients with metastatic breast cancer who underwent genomic profiling at academic institutions.

Sigma Planning Corp cut its holdings in Novartis AG (NYSE:NVS – Free Report) by 19.3% during the 4th quarter, HoldingsChannel.com reports. The fund owned 4,218 shares of the company’s stock after ...

Welcome to the PTC Therapeutics fourth quarter and full year 2024 earnings conference call. (Operator Instructions) Today's conference is being recorded. I would now like to turn the conference over ...

Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...